Over the years, I’ve seen firsthand how evolving standards and increasing demands for precision are reshaping the way the ...
MedPage Today on MSN
Practice-Influencing Results in Oligometastatic Prostate Cancer
Median progression-free survival (PFS) increased from 7.4 months with stereotactic body radiotherapy (SBRT) to 17.6 months with the addition of 177 lutetium (Lu) PNT2002 targeting prostate-specific ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback